Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Michela Tindera But despite losing Read and D’Amelio’s support, Starboard is still pushing ahead with its campaign. Yesterday, October 22nd, at an activist investor conference in New York, Starboard ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Activist investor Keith Meister is not embarrassed about lagging behind other corporate agitators, saying his rivals' work ...

Adds Kenvue comment. Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder ...

Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable ...

Starboard Value LP Chief Executive Officer Jeffrey Smith said there has been at least $20 billion in value destruction at drugmaker Pfizer Inc., which he admonished for failing to deliver on a ...

Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...